|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02561 VISEN PHARMA-B
Nominal 
19.100 -0.900 (-4.500%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 34,542 | -- | 165 | 0 | 0 | 0 |
| Cost of Sales | (16,480) | -- | (146) | 0 | -- | -- |
| Gross Profit | 18,062 | -- | 19 | 0 | -- | -- |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (9,555) | (17,365) | (16,280) | (14,301) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (104,103) | -11.792% | (253,422) | (182,242) | (249,570) | (288,967) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (104,103) | -11.792% | (253,422) | (182,242) | (249,570) | (288,967) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (2,734) | -46.371% | (10,679) | (6,609) | (10,828) | (4,948) |
| Depreciation & Amortisation | 1,791 | 148.061% | -- | 4,466 | 6,996 | 7,397 |
| Directors' Emoluments | -- | -- | -- | 29,766 | 19,069 | 62,474 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -95.000 | -19.492% | -244.000 | -195.000 | -- | -- |
| DPS (cts) | 0.000 | -- | 0.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (4.317) | (1.504) | -- | -- |
| NBV per share ($) | 5.901 | -- | 6.689 | -- | -- | -- |
| Remarks: | Real time quote last updated: 09/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -104,103 |
| %Change | -11.792% |
| EPS / (LPS) | RMB -0.950 |
| NBV Per Share (¥) | RMB 5.901 |